Volume 13 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(1): 32-37
Wu Guobin, Chen Guodong. Normothermic machine perfusion of kidney and ischemia-free kidney transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 32-37. doi: 10.3969/j.issn.1674-7445.2022.01.005
Citation: Wu Guobin, Chen Guodong. Normothermic machine perfusion of kidney and ischemia-free kidney transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(1): 32-37. doi: 10.3969/j.issn.1674-7445.2022.01.005
shu

Normothermic machine perfusion of kidney and ischemia-free kidney transplantation

doi: 10.3969/j.issn.1674-7445.2022.01.005

  • Organ Transplantation Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

More Information
  • Corresponding author: Chen Guodong, E-mail: chenguodong2000@163.com
  • Received Date: 2021-09-07
    Available Online: 2022-01-12
  • Publish Date: 2022-01-15
    Abstract
  • To increase the utilization rate of expanded criteria donor (ECD) kidney, the kidney preservation methods have been ever advancing in recent years. The application of normothermic machine perfusion (NMP) promotes the preservation, evaluation and repair of ex vivo donor kidneys and accelerates the innovation of surgical approaches of kidney transplantation. Ischemia-free kidney transplantation (IFKT), which initiated by Organ Transplantation Center of the First Affiliated Hospital of Sun Yat-sen University, keeps the blood flow and oxygen supply of the donor kidney with NMP machine during the entire process of acquisition, preservation and transplantation, thereby fundamentally avoiding ischemia-reperfusion injury (IRI) of the donor kidney and reducing the risk of delayed graft function (DGF) and acute rejection after surgery. In this article, recent progresses upon the kidney NMP, surgical procedures and short-term outcomes of IFKT were reviewed, aiming to provide reference for enhancing the utilization rate of ECD donor kidney and resolving the issue of organ shortage.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    TINGLE SJ, FIGUEIREDO RS, MOIR JA, et al. Hypothermic machine perfusion is superior to static cold storage in deceased donor kidney transplantation: a Meta-analysis[J]. Clin Transplant, 2020, 34(4): e13814. DOI: 10.1111/ctr.13814.
    [2]
    JOCHMANS I, BRAT A, DAVIES L, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial[J]. Lancet, 2020, 396(10263): 1653-1662. DOI: 10.1016/S0140-6736(20)32411-9.
    [3]
    HENDRIKS KDW, BRÜGGENWIRTH IMA, MAASSEN H, et al. Renal temperature reduction progressively favors mitochondrial ROS production over respiration in hypothermic kidney preservation[J]. J Transl Med, 2019, 17(1): 265. DOI: 10.1186/s12967-019-2013-1.
    [4]
    XU J, BUCHWALD JE, MARTINS PN. Review of current machine perfusion therapeutics for organ preservation[J]. Transplantation, 2020, 104(9): 1792-1803. DOI: 10.1097/TP.0000000000003295.
    [5]
    HE X, CHEN G, ZHU Z, et al. The first case of ischemia-free kidney transplantation in humans[J]. Front Med (Lausanne), 2019, 6: 276. DOI: 10.3389/fmed.2019.00276.
    [6]
    MINOR T, VON HORN C, GALLINAT A, et al. First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation[J]. Am J Transplant, 2020, 20(4): 1192-1195. DOI: 10.1111/ajt.15647.
    [7]
    HE X, JI F, ZHANG Z, et al. Combined liver-kidney perfusion enhances protective effects of normothermic perfusion on liver grafts from donation after cardiac death[J]. Liver Transpl, 2018, 24(1): 67-79. DOI: 10.1002/lt.24954.
    [8]
    LI J, JIA J, HE N, et al. Combined kidney-liver perfusion enhances the proliferation effects of hypothermic perfusion on liver grafts via upregulation of IL-6/STAT3 signaling[J]. Mol Med Rep, 2019, 20(2): 1663-1671. DOI: 10.3892/mmr.2019.10379.
    [9]
    ONISCU GC, RANDLE LV, MUIESAN P, et al. In situ normothermic regional perfusion for controlled donation after circulatory death--the United Kingdom experience[J]. Am J Transplant, 2014, 14(12): 2846-2854. DOI: 10.1111/ajt.12927.
    [10]
    HOSGOOD SA, NICHOLSON ML. First in man renal transplantation after ex vivo normothermic perfusion[J]. Transplantation, 2011, 92(7): 735-738. DOI: 10.1097/TP.0b013e31822d4e04.
    [11]
    NICHOLSON ML, HOSGOOD SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study[J]. Am J Transplant, 2013, 13(5): 1246-1252. DOI: 10.1111/ajt.12179.
    [12]
    URBANELLIS P, HAMAR M, KATHS JM, et al. Normothermic ex vivo kidney perfusion improves early DCD graft function compared with hypothermic machine perfusion and static cold storage[J]. Transplantation, 2020, 104(5): 947-955. DOI: 10.1097/TP.0000000000003066.
    [13]
    HOSGOOD SA, SAEB-PARSY K, WILSON C, et al. Protocol of a randomised controlled, open-label trial of ex vivo normothermic perfusion versus static cold storage in donation after circulatory death renal transplantation[J]. BMJ Open, 2017, 7(1): e012237. DOI: 10.1136/bmjopen-2016-012237.
    [14]
    THOMPSON ER, CONNELLY C, ALI S, et al. Cell therapy during machine perfusion[J]. Transpl Int, 2021, 34(1): 49-58. DOI: 10.1111/tri.13780.
    [15]
    HE X, GUO Z, ZHAO Q, et al. The first case of ischemia-free organ transplantation in humans: a proof of concept[J]. Am J Transplant, 2018, 18(3): 737-744. DOI: 10.1111/ajt.14583.
    [16]
    O'NEILL S, SRINIVASA S, CALLAGHAN CJ, et al. Novel organ perfusion and preservation strategies in transplantation - where are we going in the United Kingdom?[J]. Transplantation, 2020, 104(9): 1813-1824. DOI: 10.1097/TP.0000000000003106.
    [17]
    DE BEULE J, JOCHMANS I. Kidney perfusion as an organ quality assessment tool-are we counting our chickens before they have hatched?[J]. J Clin Med, 2020, 9(3): 879. DOI: 10.3390/jcm9030879.
    [18]
    TCHOUTA LN, ALGHANEM F, ROJAS-PENA A, et al. Prolonged (≥24 hours) normothermic (≥32 ℃) ex vivo organ perfusion: lessons from the literature[J]. Transplantation, 2021, 105(5): 986-998. DOI: 10.1097/TP.0000000000003475.
    [19]
    HAMEED AM, LU DB, PATRICK E, et al. Brief normothermic machine perfusion rejuvenates discarded human kidneys[J]. Transplant Direct, 2019, 5(11): e502. DOI: 10.1097/TXD.0000000000000944.
    [20]
    ROZENBERG K, KNIJFF L, LOFARO L, et al. Normothermic machine perfusion of kidneys allows assessment of mitochondrial respiration and facilitates recovery following kidney injury[J]. Transpl Int, 2019, 32(S2): 157.
    [21]
    FERDINAND JR, HOSGOOD SA, MOORE T, et al. Cytokine absorption during human kidney perfusion reduces delayed graft function-associated inflammatory gene signature[J]. Am J Transplant, 2021, 21(6): 2188-2199. DOI: 10.1111/ajt.16371.
    [22]
    THOMPSON E, BATES L, IBRAHIM I, et al. Reconditioning marginal human kidneys using multistemtm cell therapy delivered during normothermic machine perfusion[J]. Transpl Int, 2019, 32(S2): 5-6.
    [23]
    YUZEFOVYCH Y, VALDIVIA E, RONG S, et al. Genetic engineering of the kidney to permanently silence MHC transcripts during ex vivo organ perfusion[J]. Front Immunol, 2020, 11: 265. DOI: 10.3389/fimmu.2020.00265.
    [24]
    TIETJEN GT, HOSGOOD SA, DIRITO J, et al. Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys[J]. Sci Transl Med, 2017, 9(418): eaam6764. DOI: 10.1126/scitranslmed.aam6764.
    [25]
    HUANG Y, WANG J, JIANG K, et al. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions[J]. J Control Release, 2021, 334: 127-137. DOI: 10.1016/j.jconrel.2021.04.016.
    [26]
    HAMEED AM, LU DB, BURNS H, et al. Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform[J]. Sci Rep, 2020, 10(1): 6930. DOI: 10.1038/s41598-020-63687-0.
    [27]
    FRANZIN R, STASI A, FIORENTINO M, et al. Renal delivery of pharmacologic agents during machine perfusion to prevent ischaemia-reperfusion injury: from murine model to clinical trials[J]. Front Immunol, 2021, 12: 673562. DOI: 10.3389/fimmu.2021.673562.
    [28]
    DIRITO JR, HOSGOOD SA, RESCHKE M, et al. Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys[J]. Am J Transplant, 2021, 21(1): 161-173. DOI: 10.1111/ajt.16148.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (495) PDF downloads(133) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return